Muplestim
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Muplestim
- DrugBank Accession Number
- DB12431
- Background
Muplestim is under investigation in clinical trial NCT00002258 (A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia).
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Other protein based therapies - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Human interleukin-3 (nonglycosylated)
- Interleukin 3
- Interleukin 3 (human)
- Interleukin-3
- Interleukin-3 human (recombinant)
- Multipotential colony-stimulating factor
- Muplestim
- External IDs
- Interleukin 3
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareCyclophosphamide The risk or severity of pulmonary toxicity can be increased when Muplestim is combined with Cyclophosphamide. Vinblastine The risk or severity of peripheral neuropathy can be increased when Muplestim is combined with Vinblastine. Vincristine The risk or severity of peripheral neuropathy can be increased when Muplestim is combined with Vincristine. Vindesine The risk or severity of peripheral neuropathy can be increased when Muplestim is combined with Vindesine. Vinflunine The risk or severity of peripheral neuropathy can be increased when Muplestim is combined with Vinflunine. Vinorelbine The risk or severity of peripheral neuropathy can be increased when Muplestim is combined with Vinorelbine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- A802907MI4
- CAS number
- 148641-02-5
References
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Recruiting Treatment Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) 2 1 Completed Treatment Cytopenias / Human Immunodeficiency Virus (HIV) Infections 1 1 Terminated Supportive Care Malignant Lymphomas / Neutropenia 1 1, 2 Completed Treatment Breast Cancer / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic/Myeloproliferative Diseases 1 1, 2 Not Yet Recruiting Treatment Lymphoblastic lymphoma (Precursor T-lymphoblastic lymphoma/leukemia) refractory / Recurrent Adult Lymphoblastic Lymphoma / Recurrent B Acute Lymphoblastic Leukemia / Recurrent T Acute Lymphoblastic Leukemia / Refractory B Acute Lymphoblastic Leukemia / Refractory T Acute Lymphoblastic Leukemia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on October 20, 2016 22:22 / Updated on February 21, 2021 18:53